Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection.

Yuen T, Brouillette MJ, Fellows LK, Ellis RJ, Letendre S, Heaton R, Mayo N; CHARTER group,.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):48-54. doi: 10.1097/QAI.0000000000001466.

PMID:
28797021
2.

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Franklin DR, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Infect Dis. 2017 Jan 1;215(1):105-113. doi: 10.1093/infdis/jiw505. Epub 2016 Oct 26.

PMID:
27789723
3.

Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining "symptomatic" versus "asymptomatic" HAND.

Obermeit LC, Beltran J, Casaletto KB, Franklin DR, Letendre S, Ellis R, Fennema-Notestine C, Vaida F, Collier AC, Marra CM, Clifford D, Gelman B, Sacktor N, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group.

J Neurovirol. 2017 Feb;23(1):67-78. doi: 10.1007/s13365-016-0474-z. Epub 2016 Aug 24.

PMID:
27557777
4.

HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex.

Keltner JR, Connolly CG, Vaida F, Jenkinson M, Fennema-Notestine C, Archibald S, Akkari C, Schlein A, Lee J, Wang D, Kim S, Li H, Rennels A, Miller DJ, Kesidis G, Franklin DR, Sanders C, Corkran S, Grant I, Brown GG, Atkinson JH, Ellis RJ; CHARTER Group.

Pain Med. 2017 Mar 1;18(3):428-440. doi: 10.1093/pm/pnw180.

5.

The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth.

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group.

J Neurovirol. 2016 Dec;22(6):823-830. Epub 2016 Jun 6.

6.

Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals.

Cooley SA, Paul RH, Fennema-Notestine C, Morgan EE, Vaida F, Deng Q, Chen JA, Letendre S, Ellis R, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Ances BM; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group.

J Neurovirol. 2016 Oct;22(5):607-614. Epub 2016 Mar 28.

PMID:
27021072
7.

Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study.

Hammond ER, Crum RM, Treisman GJ, Mehta SH, Clifford DB, Ellis RJ, Gelman BB, Grant I, Letendre SL, Marra CM, Morgello S, Simpson DM, Mcarthur JC; CHARTER Group.

J Neurovirol. 2016 Aug;22(4):479-87. doi: 10.1007/s13365-015-0416-1. Epub 2016 Jan 4.

8.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2016 Apr;22(2):170-8. doi: 10.1007/s13365-015-0382-7. Epub 2015 Sep 25.

9.

Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.

Hulgan T, Samuels DC, Bush W, Ellis RJ, Letendre SL, Heaton RK, Franklin DR, Straub P, Murdock DG, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, Kallianpur AR; CHARTER Group.

Clin Infect Dis. 2015 Nov 1;61(9):1476-84. doi: 10.1093/cid/civ527. Epub 2015 Jun 30.

10.

CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease.

Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2015 Oct;21(5):559-67. doi: 10.1007/s13365-015-0359-6. Epub 2015 Jun 12.

11.

Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group.

J Neurovirol. 2015 Aug;21(4):439-48. doi: 10.1007/s13365-015-0333-3. Epub 2015 Mar 17.

12.

Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.

Malvar J, Vaida F, Sanders CF, Atkinson JH, Bohannon W, Keltner J, Robinson-Papp J, Simpson DM, Marra CM, Clifford DB, Gelman B, Fan J, Grant I, Ellis RJ; CHARTER Group.

Pain. 2015 Apr;156(4):731-9. doi: 10.1097/01.j.pain.0000461252.75089.bf.

13.

Reply to Haddow et al.

Heaton RK, Franklin DR Jr, Deutsch R, Letendre SL, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I; CHARTER Group.

Clin Infect Dis. 2015 May 1;60(9):1442-3. doi: 10.1093/cid/civ045. Epub 2015 Feb 2. No abstract available.

14.

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people.

Clifford DB, Vaida F, Kao YT, Franklin DR, Letendre SL, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Grant I, Heaton RK; CHARTER Group.

Neurology. 2015 Jan 20;84(3):241-50. doi: 10.1212/WNL.0000000000001156. Epub 2014 Dec 10.

15.

Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation.

Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, Ellis R, Franklin D, Aldrovandi G, Marra CM, Clifford D, Morgello S, Grant I, McCutchan JA; CHARTER Group.

J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):281-8. doi: 10.1097/QAI.0000000000000458.

16.

Psychometric validation of the BDI-II among HIV-positive CHARTER study participants.

Hobkirk AL, Starosta AJ, De Leo JA, Marra CM, Heaton RK, Earleywine M; CHARTER Group.

Psychol Assess. 2015 Jun;27(2):457-66. doi: 10.1037/pas0000040. Epub 2014 Nov 24.

17.

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I; CHARTER Group.

Clin Infect Dis. 2015 Feb 1;60(3):473-80. doi: 10.1093/cid/ciu862. Epub 2014 Oct 31.

18.

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study.

Archibald SL, McCutchan JA, Sanders C, Wolfson T, Jernigan TL, Ellis RJ, Ances BM, Collier AC, McArthur JC, Morgello S, Simpson DM, Marra C, Gelman BB, Clifford DB, Grant I, Fennema-Notestine C; CHARTER Group.

J Neurovirol. 2014 Dec;20(6):603-11. doi: 10.1007/s13365-014-0284-0. Epub 2014 Sep 17.

19.

The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

Hammond ER, Crum RM, Treisman GJ, Mehta SH, Marra CM, Clifford DB, Morgello S, Simpson DM, Gelman BB, Ellis RJ, Grant I, Letendre SL, McArthur JC; CHARTER Group.

Am J Epidemiol. 2014 Aug 1;180(3):297-307. doi: 10.1093/aje/kwu098. Epub 2014 Jun 24.

20.

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Grant I, Franklin DR Jr, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK; CHARTER Group.

Neurology. 2014 Jun 10;82(23):2055-62. doi: 10.1212/WNL.0000000000000492. Epub 2014 May 9.

Supplemental Content

Loading ...
Support Center